Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019327 · ClinicalTrials.gov registry record · Phase 1
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04019327: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04019327 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04019327, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer. The purpose of Phase II is to test the efficacy (effectiveness) of talazoparib and temozolomide at the maximum tolerated dose, which was determined to be 1mg talazoparib and 75mg/m² temozolomide in the Phase Ib portion of this study.
Interventions
- DRUG Temozolomide
- DRUG Talazoparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019327
The ClinicalTrials.gov registry entry for NCT04019327 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT04019327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04019327 about?
NCT04019327 is a clinical study titled "A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer". The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer. The purpose of Phase II is to test the efficacy (effectiveness) of talazoparib and temozolomide at the maximum tolerated dose, which...
What is the current status of trial NCT04019327?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-07-11. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT04019327?
The interventions under investigation include: Temozolomide (DRUG), Talazoparib (DRUG).
Who is sponsoring clinical trial NCT04019327?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.